BR112016027825A2 - - Google Patents
Info
- Publication number
- BR112016027825A2 BR112016027825A2 BR112016027825A BR112016027825A BR112016027825A2 BR 112016027825 A2 BR112016027825 A2 BR 112016027825A2 BR 112016027825 A BR112016027825 A BR 112016027825A BR 112016027825 A BR112016027825 A BR 112016027825A BR 112016027825 A2 BR112016027825 A2 BR 112016027825A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382209.6 | 2014-06-02 | ||
| EP14382209 | 2014-06-02 | ||
| PCT/EP2015/001115 WO2015185209A1 (en) | 2014-06-02 | 2015-06-02 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016027825A2 true BR112016027825A2 (pt) | 2017-08-22 |
| BR112016027825B1 BR112016027825B1 (pt) | 2023-03-28 |
Family
ID=50972618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016027825-9A BR112016027825B1 (pt) | 2014-06-02 | 2015-06-02 | Derivados alquílicos de compostos de 1-oxa-4,9-diazaspiro-undecano, processos para sua preparação e composição farmacêutica compreendendo os mesmos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10246465B2 (pt) |
| EP (1) | EP3149006B1 (pt) |
| JP (1) | JP6611736B2 (pt) |
| KR (1) | KR102468874B1 (pt) |
| CN (1) | CN106414457B (pt) |
| AR (1) | AR100715A1 (pt) |
| AU (1) | AU2015271248B2 (pt) |
| BR (1) | BR112016027825B1 (pt) |
| CA (1) | CA2949573C (pt) |
| IL (1) | IL249016B (pt) |
| MX (1) | MX2016015760A (pt) |
| MY (1) | MY177365A (pt) |
| NZ (1) | NZ726476A (pt) |
| PH (1) | PH12016502307A1 (pt) |
| RU (1) | RU2720406C2 (pt) |
| SG (2) | SG11201609632UA (pt) |
| TN (1) | TN2016000509A1 (pt) |
| TW (1) | TWI685497B (pt) |
| UA (1) | UA124049C2 (pt) |
| WO (1) | WO2015185209A1 (pt) |
| ZA (1) | ZA201608079B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201615643A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| ES2794801T3 (es) * | 2015-10-23 | 2020-11-19 | Esteve Pharmaceuticals Sa | Compuestos oxaazaespíricos con actividad contra el dolor |
| JP6884973B2 (ja) | 2015-10-23 | 2021-06-09 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 疼痛に対して活性を有するオキサジアザスピロ化合物 |
| LT3377500T (lt) | 2015-11-16 | 2022-12-12 | Esteve Pharmaceuticals, S.A. | Oksadiazaspiro junginiai, skirti piktnaudžiavimo narkotikais arba priklausomybės nuo jų gydymui |
| ES2823588T3 (es) * | 2016-05-20 | 2021-05-07 | Esteve Pharmaceuticals Sa | Derivados de tetrahidropirano que tienen actividad multimodal contra el dolor |
| US11236110B2 (en) * | 2017-10-17 | 2022-02-01 | Esteve Pharmaceuticals, S.A. | Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one |
| WO2019158634A1 (en) | 2018-02-16 | 2019-08-22 | Esteve Pharmaceuticals, S.A. | Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one |
| WO2019180188A1 (en) * | 2018-03-23 | 2019-09-26 | Esteve Pharmaceuticals, S.A. | Aminopropoxyphenyl and benzyl 1-oxa-4,9-diazaspiroundecane derivatives having multimodal activity against pain |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| WO2021018824A1 (en) | 2019-07-31 | 2021-02-04 | Esteve Pharmaceuticals, S.A. | Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133610B1 (pt) * | 1971-04-15 | 1975-10-31 | Sumitomo Chemical Co | |
| US4332804A (en) * | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| CA2557354C (en) * | 2004-03-03 | 2013-05-07 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
| DE102005030061A1 (de) | 2005-06-27 | 2006-12-28 | Behr Gmbh & Co. Kg | Klimagerät |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
| AU2008219980B2 (en) | 2007-03-01 | 2012-01-12 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| JP2010538003A (ja) | 2007-08-29 | 2010-12-09 | グラクソスミスクライン エルエルシー | チアゾールおよびオキサゾールキナーゼ阻害薬 |
| PL2242759T3 (pl) * | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
| MX347982B (es) * | 2011-03-14 | 2017-05-22 | Vertex Pharma | Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos. |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| WO2015017305A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibitors of the renal outer medullary potassium channel |
| TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 |
| TW201615643A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
-
2015
- 2015-06-01 TW TW104117583A patent/TWI685497B/zh active
- 2015-06-02 WO PCT/EP2015/001115 patent/WO2015185209A1/en active Application Filing
- 2015-06-02 KR KR1020167036612A patent/KR102468874B1/ko active IP Right Grant
- 2015-06-02 SG SG11201609632UA patent/SG11201609632UA/en unknown
- 2015-06-02 CA CA2949573A patent/CA2949573C/en active Active
- 2015-06-02 MX MX2016015760A patent/MX2016015760A/es unknown
- 2015-06-02 AR ARP150101746A patent/AR100715A1/es active IP Right Grant
- 2015-06-02 RU RU2016150518A patent/RU2720406C2/ru active
- 2015-06-02 EP EP15725236.2A patent/EP3149006B1/en active Active
- 2015-06-02 JP JP2016570805A patent/JP6611736B2/ja active Active
- 2015-06-02 US US15/315,486 patent/US10246465B2/en active Active
- 2015-06-02 UA UAA201613478A patent/UA124049C2/uk unknown
- 2015-06-02 BR BR112016027825-9A patent/BR112016027825B1/pt active IP Right Grant
- 2015-06-02 TN TN2016000509A patent/TN2016000509A1/en unknown
- 2015-06-02 NZ NZ726476A patent/NZ726476A/en unknown
- 2015-06-02 SG SG10201810660QA patent/SG10201810660QA/en unknown
- 2015-06-02 CN CN201580029239.4A patent/CN106414457B/zh active Active
- 2015-06-02 MY MYPI2016704255A patent/MY177365A/en unknown
- 2015-06-02 AU AU2015271248A patent/AU2015271248B2/en active Active
-
2016
- 2016-11-16 IL IL249016A patent/IL249016B/en not_active IP Right Cessation
- 2016-11-18 PH PH12016502307A patent/PH12016502307A1/en unknown
- 2016-11-22 ZA ZA2016/08079A patent/ZA201608079B/en unknown
-
2019
- 2019-02-14 US US16/275,676 patent/US20190177337A1/en not_active Abandoned
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: ESTEVE PHARMACEUTICALS, S.A. (ES) |
|
| B25G | Requested change of headquarter approved |
Owner name: ESTEVE PHARMACEUTICALS, S.A. (ES) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25A | Requested transfer of rights approved |
Owner name: ACONDICIONAMIENTO TARRASENSE (ES) |